Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for MEK1 2
Most Correlated Studies
- Melanoma Me13 cells treated with MEK1/2, PI3K/mTOR, mTOR, and BRAF V600E inhibitors
- SK-MEL-28 melanoma cells with anthrax lethal toxin-induced knockdown of MEK1 and MEK2
- Lung cancer A549 and Calu-6 cells treated with pimasertib
- Melanoma cell line treated with MEK and PI3K/mTOR inhibitors
- Colorectal cancer organoids derived from patients and treated with trametinib and PRI-724
Most Relevant Literature
- Role of Superoxide Reductase FA796 in Oxidative Stress Resistance in Filifactor alocis.
- The disruption of the MAPKK gene triggering the synthesis of flavonoids in endophytic fungus Phomops…
- Genome-wide identification and expression profiling of thes MAPK, MAPKK, and MAPKKK gene families in…
- E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers.
- Arabidopsis MAPKKK δ-1 is required for full immunity against bacterial and fungal infection.
Most Relevant Clinical Trials
- Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in…
- A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF…
- Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in…
